Flooding significantly hampers global forage production. In flood-prone regions, Lotus tenuis and Lotus corniculatus are common forage legumes, yet little is known about their responses to partial or complete submergence. To address this, we evaluated 10 Lotus accessions subjected to 11days of either partial or complete submergence, analysing growth traits related to tolerance and recovery after de-submergence. Principal component analyses revealed that submergence associated growth parameters were linked to L. corniculatus accessions, whereas recovery was associated with L. tenuis accessions. Notably, in L. tenuis , recovery from complete submergence positively correlated with leaf mass fraction but negatively with root mass fraction, showing an opposite pattern than in L. corniculatus . Encouragingly, no trade-off was found between inherent growth capacity and submergence tolerance (both partial and complete) or recovery ability, suggesting genetic selection for increased tolerance would not compromise growth potential. L. tenuis exhibited accessions with both partial and complete submergence tolerance, making them versatile for flood-prone environments, whereas L. corniculatus accessions were better suited for partial submergence. These findings offer valuable insights to enhance forage production in flood-prone areas and guide the selection of appropriate Lotus accessions for specific flood conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1071/FP23172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Clin Cancer Res
January 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On April 23, 2024, FDA granted accelerated approval to tovorafenib, a type II RAF kinase inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Efficacy was evaluated in FIREFLY-1 (NCT04775485), a single-arm, open-label, multicenter trial that enrolled patients 6 months to 25 years of age with relapsed or refractory pLGG with an activating BRAF alteration who had received prior systemic therapy. The major efficacy outcome measure was radiologic overall response rate (ORR), defined as the proportion of patients with complete response, partial response, or minor response as determined by blinded independent central review using Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.
View Article and Find Full Text PDFEfficacy of Methotrexate and Anti-TNF Combination Therapy in Adults with Refractory Crohn's Disease.
Middle East J Dig Dis
October 2024
Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Biological medications have played a significant role in maintenance therapy for Crohn's disease (CD), but some cases become refractory to these agents. Methotrexate (MTX) appears to be a cost-effective and readily available drug for enhancing the effectiveness of maintenance therapy when used in combination with anti-tumor necrosis factor (anti-TNF) therapy in such cases. However, its effectiveness is still to be established.
View Article and Find Full Text PDFOutcomes following resective and disconnective strategies in the treatment of epileptic spasms: a systematic review of the literature and individual patient data meta-analysis.
Front Neurol
December 2024
Brain and Development Research Axis, Azrieli CHU Ste-Justine Research Center, Montreal, QC, Canada.
Epileptic spasms (ES) are a unique seizure type typically presenting in the form of infantile epileptic spasms syndrome (IESS) with characteristic hypsarrhythmia on scalp EEG and a preponderance with developmental delay or regression. While pharmacotherapy is the mainstay of treatment, surgical options, including disconnective or resective procedures, are increasingly recognized as viable therapeutic options for recurrent or persistent ES. However, limited data on safety, effectiveness, and prognostic factors hinder informed decision-making regarding surgery indications, timing, and intervention type.
View Article and Find Full Text PDF[Anticoagulation effects of nafamostat mesylate in sustained low-efficiency dialysis and its relevant factors].
Zhonghua Yi Xue Za Zhi
January 2025
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai Medical Center of Kidney, Shanghai200032, China.
To investigate anticoagulation effects of nafamostat mesylate(NM) in sustained low-efficiency dialysis (SLED) and its relevant factors. Critically ill patients with kidney disease who were admitted to Zhongshan Hospital Affiliated to Fudan University and underwent SLED treatment from May to August 2024 were retrospectively included. Baseline clinical data were collected, and the activated partial thromboplastin time (APTT) and activated clotting time (ACT) were measured at the arterial end, before the filter, and at the venous end two hours post-NM anticoagulation treatment.
View Article and Find Full Text PDFComparison of the Efficacy and Safety of PD-1/PD-L1 Inhibitors in the Treatment of Small Cell Lung Cancer.
Cancer Rep (Hoboken)
January 2025
Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China.
Objective: This study aims to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in treating small-cell lung cancer (SCLC) and determine the role of PD-1 monoclonal antibodies in improving patient outcomes.
Methods: A retrospective analysis was performed on 37 SCLC patients who received PD-1 or PD-L1 inhibitors along with chemotherapy at the First Hospital of Lanzhou University between June 2018 and June 2023. Treatment effectiveness was measured by overall response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS), utilizing chi-square and T-tests, along with Kaplan-Meier and log-rank analyses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!